# Neonc Technologies

Source: https://onco.cc/companies/neonc-technologies/  
OnCo record `neonc-technologies` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Neonc Technologies is a United States-based biotechnology company running 3 late-stage cancer trials of NEO212 Oral and NEO100 in glioma & glioblastoma, cervical cancer and colorectal cancer.

## Summary

Neonc Technologies, based in Calabasas, the United States, is a biotechnology company listed as NASDAQ: NTHI. NeOnc develops drug delivery therapeutics for central nervous system diseases, using a perillyl-alcohol-based platform intended to transport therapeutics across the blood-brain barrier. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials, testing NEO212 Oral and NEO100 in glioma & glioblastoma, cervical cancer, colorectal cancer, oesophageal cancer and gastric & gastro-oesophageal junction cancer. The largest, NCT06047379 (Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis), plans to enrol 134 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Neonc Technologies, Inc.
- Tags: ctgov-sponsor
- HQ: Calabasas
- Type: biotech
- Website: https://www.neonc.com
- Ticker: NASDAQ: NTHI

## Sources

- Official website: https://www.neonc.com
- ClinicalTrials.gov: trials led by Neonc Technologies: https://clinicaltrials.gov/search?lead=Neonc%20Technologies%2C%20Inc.

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Melanoma](https://onco.cc/cancers/melanoma/), [Merkel cell carcinoma](https://onco.cc/cancers/merkel-cell-carcinoma/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- trials: [Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis](https://onco.cc/trials/nct06047379/), [Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma](https://onco.cc/trials/nct02704858/)

---
JSON: https://onco.cc/api/v1/entities/neonc-technologies.json